Efficacy and safety of pyrotinib in the treatment of HER2-positive liver metastatic advanced breast cancer.

Front Oncol · 2025 · PMC12011879 · PMID 40265017

Europe PMC DOI

hedged sentence

0.0510

closest p · 1.0× alpha

0.0510

boldest claim

The sentences

did not reach statistical significanceP = 0.051so close (0.05 < p ≤ 0.1)

However, patients with negative PR expression exhibited a trend toward longer median OS (20 months), although this difference did not reach statistical significance (P = 0.051).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.